Modulated Protein Binding Ability of Anti-Diabetic Drugs in Presence of Monodispersed Gold Nanoparticles and its Inhibitory Potential towards Advanced Glycated End (AGE) Product Formation
- 31 Downloads
Binding strength of the anti-diabetic drugs chlorpropamide (CPM) and tolbutamide (TBM) with model protein bovine serum albumin (BSA) shows strong modulation in presence of colloidal gold nanoparticles (AuNP). Intrinsic tryptophan fluorescence of both the native BSA and BSA-AuNP conjugate quenched in presence of the drugs. Stern-Volmer quenching constant (KSV) of CPM binding to BSA-AuNP conjugate at different temperatures is almost twice (6.76~14.76 × 103 M−1) than the corresponding values in native BSA (3.21~5.72 × 103 M−1). However, the calculated KSV values with TBM show certain degree of reduction in presence of AuNP (6.46× 103 M−1), while comparing with native BSA (8.83 × 103 M−1). The binding mode of CPM towards BSA-AuNP conjugate is mainly through hydrophobic forces; whereas, TBM binding is identified to be Van der Waal’s and hydrogen bonding type of interaction. Fluorescence lifetime analysis confirms static type of quenching for the intrinsic tryptophan fluorescence of BSA as well as BSA-AuNP conjugate with addition of CPM and TBM at different concentrations. The α-helical content in the secondary structure of BSA is decreased to 48.32% and 45. 28% in presence of AuNP, when the concentration of CPM is 0.08 mM and 0.16 mM in comparison with that of native protein (50.13%). On the other hand, the intensity of sugar induced advanced glycated end (AGE) product fluorescence is decreased by 55% and 80% at 0.13 nM and 0.68 nM AuNP, respectively. Change in the binding strength of the drugs with transport protein and reduced AGE product formation in presence of AuNP could lead to a major development in the field of nanomedicine and associated drug delivery techniques.
KeywordsSerum albumin Drug binding AGE product Nanomedicine Fluorescence
The authours acknowledge the support from Department of Nanotechnology, NEHU for the characterization of BSA-AuNP conjugate. Thanks are also due to the Dept. of Science & Technology (DST), Govt. of India for supporting the Chemistry Department through FIST program (SR/FST/CSI-194/2008). IRS is a recipient of research fellowship from NEHU.
- 7.Vetter SW, Glycated Serum Albumin and AGE Receptors, in: G.S. Makowski (Ed.) Advances in Clinical Chemistry, Ch 5, Elsevier, 2015, pp. 205–275Google Scholar
- 8.Uversky VN, Ashraf JM, Rabbani G, Ahmad S, Hasan Q, Khan RH, Alam K, Choi I (2015) Glycation of H1 histone by 3-Deoxyglucosone: effects on protein structure and generation of different advanced Glycation end products. Plos one, 10, https://doi.org/10.1371/journal.pone.0130630 PubMedPubMedCentralCrossRefGoogle Scholar
- 10.Rahnama E, Mahmoodian-Moghaddam M, Khorsand-Ahmadi S, Saberi MR, Chamani J (2014) Binding site identification of metformin to human serum albumin and glycated human serum albumin by spectroscopic and molecular modeling techniques: a comparison study. J Biomol Struct Dyn 33:513–533PubMedCrossRefGoogle Scholar
- 17.Lage ACP, Chaves CR, Frezard FJG, Aguilar JLL, Ladeira LO, de Almeida, RFM, Toshio R, Ferreira SR, Gold nanoparticles coated by antibiotics, and its production method, pharmaceutical compositions for treatment of infectious diseases, in: Braz. Pedido, 2018Google Scholar
- 43.Valeur B (2002) Molecular fluorescence principles and applications. Wiley-VCH, Weinheim, FRGGoogle Scholar
- 57.Obayashi H, Nakano K, Shigeta H, Yamaguchi M, Yoshimori K, Fukui M, Fujii M, Kitagawa Y, Nakamura N, Nakamura K, Nakazawa Y, Ienaga K, Ohta M, Nishimura M, Fukui I, Kondo M (1996) Formation of Crossline as a fluorescent advanced Glycation end product in vitro and in vivo. Biochem Biophys Res Commun 226:37–41PubMedCrossRefGoogle Scholar
- 58.Hori M, Yagi M, Nomoto K, Ichijo R, Shimode A, Kitano T, Yonei Y (2012) Experimental models for advanced Glycation end product formation using albumin, collagen, elastin, keratin and proteoglycan. Anti-Ageing Medicine 9:125–134Google Scholar